Introduction
The small cell variant of bronchial carcinoma constitutes approximately 25% of all cases of lung cancer and in the last decade has provided not only one ofthe greatest challenges in solid tumour therapy but also given important clues to the nature of neoplastic transformation. Pathologists recognized the existence of small cell carcinoma following the work by Barnard in 1926 demonstrating its bronchial origin1, but it was only in 1962 that Watson and Berg described the distinct clinical behaviour of this form of the disease2. During the last 20 years there has been significant progress in therapy although hopes of 'cure ' have not yet been realized despite a massive literature of clinical trials and scientific experimentation.
The principle aetiological factor in small cell carcinoma as in the vast majority of bronchial carcinomas in man, is tobacco smoking and it is therefore relevant to see how this habit became widespread throughout the World to appreciate the formidable problems involved in introducing antismoking legislation and thereby reduce the incidence of the disease.
Christopher Columbus is credited with being the first European to smoke in 1492 when he was offered tobacco by the New World Indians and this led to Spain and Portugal becoming the first countries to introduce tobacco smoking in 1558 with most other countries following by about 1600. Shipping oftobacco in the 17th century assisted in the development of Britain's Merchant Navy. Initially only pipe smoking was practised but in the 1850s commercial cigarette manufacture began. For many countries, including developing countries, tobacco has now become a valuable export3.
Aetiology
At first, smoking was recommended for medicinal reasons although Sommering in 1795 first suggested that cancer of the lip might be caused by pipe smoking. Such evidence was often overlooked and it was another 100 years before Rothman noted a high incidence of lung cancer in tobacco workers3. Only in 1950 with the studies of Doll and Hill4 and others was the idea accepted that smoking causes lung cancer. Further epidemiological studies have since shown unequivocally that smoking causes over 90% of lung cancers and that this applies equally well to small cell lung cancer as other types5.
A link between lung cancer and occupation was first described by Harting and Hesse in 18786 who drew attention to a high incidence of lung cancer among Schneeberg miners in Saxony who were prone to a fatal chronic pulmonary disorder. Originally known as 'bronchial katarrh' and attributed to an endemic occupational hazard of the mountain region, Hesse noted that the physical findings were compatible with lung cancer. Only later was the 'Bergkrankenheit' identified as bronchogenic carcinoma. The predominant histological cell type in these miners is small cell carcinoma which in early texts7 is termed sarcoma of the mediastinum. It is now clear that the causative agent of lung cancer in these miners was alphaemitting radon, which is a natural decay product of uranium mined in these areas. Certain other occupational hazards have been found to be linked more frequently with small cell lung cancer than other histological types including inhalation of chloromethylethers which may lead to small cell lung cancer in up to 68% of individuals developing lung cancer as a result of exposure5. There are also reports of small cell lung cancer due to asbestos, nickel, cadmium, arsenic, chromate and acrylonitrile.
Clinical diagnosis
It is likely that early cases of lung cancer were incorrectly diagnosed as pneumonia, particularly tuberculous but in 1815 Laennec's work entitled 'Encephaloides' laid down the descriptive findings to establish lung cancer as a disease entity8. The name was derived from the outward appearance of the tumour which grossly resembled brain tissue.
Several workers in the mid-19th century made clinical observations regarding lung cancer which hold true today and in 1895 Cockle wrote 'deposits in the brain and meninges play an important part in the clinical history of thoracic cancer'9. For lung cancer and small cell carcinoma in particular, the development of cerebral metastases has become a central management issue.
Very few lung cancers in the 1800s were diagnosed in life and Skoda (1853) and Hope (1834)9 observed that to be clinically detectable 'encephaloid tumours' had to be of considerable extent and even then might elude diagnosis ifcentrally placed and surrounded by healthy lung. By the 1890s several important developments had taken place which dramatically changed clinical practice in respect of lung cancer: in 1895 Killian performed the first bronchoscopy, the X-ray machine was introduced and sputum cytology was first used in 18989.
The area of clinical diagnosis provided many ofthe advances which occurred between 1900 and 1930 and diagnostic accuracy improved from less than 10% to around 50% in this 30-year period'0. For much of this time, disorders such as tuberculosis, syphilis and anthracosis were considered to be the major causes of lung neoplasms and the observations on metaplasia as a pre-cancerous lesion suggested a link with chronic irritation but whilst there was no doubt that lung cancer became more frequent between 1900 and 1930 it was unclear at that time whether the increase was real, due to increased levels of possible carcinogens in the environment, or apparent, due to improvements in diagnosis.
Pathology
Initially small cell cancer was classified as a primary sarcoma7, but in 1926 Barnard' demonstrated that tumours previously described as 'oat-celled sarcoma ofthe mediastinum' were clearly primary carcinomas of the lung. Reviewing 19 intrathoracic tumours he showed seven to be obvious carcinomas containing the classical 'oat' cells described in series of mediastinal sarcomas. In the remaining 12/19 cases he noted central tumours associated with a large mediastinal mass and the microscopical appearances of oat-cell neoplasms. Cell types were also present which were typical of carcinomas of bronchial origin and he concluded that 'oat-celled sarcoma ofthe mediastinum' was a misnomer.
Contemporary histological and ultrastructural studies have shown unequivocally that small cell carcinoma is a distinct pathological entity" following the original light microscopic description by Azzopardi in 195912 who listed six features in addition to the typical appearance of small oval cells with darkly staining nuclei and scanty cytoplasm. These were cell streams, ribbons, pseudosettes and rosettes; tubules and ductules, and haematoxyphil staining of blood vessel walls, attributed to DNA released from tumour cells.
Watson and Berg in 19622 found 386 cases of oat cell carcinoma amongst 3600 of lung cancer registered in New York. They rejected the arguments that small cell carcinomas were pleomorphic adenocarcinomas or poorly differentiated epidermoid carcinomas and described the specific clinical features of a large central mass on the chest radiograph, early spread, responsiveness to nitrogen mustard and a high incidence of distant metastases at post mortem. Their findings established the disease as a distinct clinical entity and in conjunction with pathological evidence it became clear that small cell carcinoma of the bronchus should be regarded as a distinct lesion, the behaviour of which was to determine the manner in which treatment programmes subsequently developed.
Treatment
In 1913, Morriston-Davies'3 reported the use of lobectomy for a primary bronchial carcinoma. Between then and 1933 further advances in thoracic surgery were only possible with developments in anaesthetic technique and the introduction of cuffed tubes. In 1933 Evarts-Graham17 carried out a successful left pneumonectomy on a patient who lived for many years. He also inserted seven radon seeds around the bronchial stump thereby giving adjuvarnt radiotherapy to his patient. Paterson in 19281' had reported his experience with high voltage roentgen ray treatment and observed a marked palliative effect, although no cures.
During the 1950s it had been shown conclusively that lobectomy where technically feasible should be performed in preference to pneumonectomy and in his series, Belcher in 195916 found a 5-year survival rate of 37% in 42 patients with small cell carcinoma treated by lobectomy.
By 1969 the Medical Research Council'7 had reported the results of treatment for small cell carcinoma in a randomized trial comparing surgery against radiotherapy. The results showed a slight advantage for radiotherapy and partly as a consequence of these results surgery was almost entirely abandoned as the primary treatment for small-cell carcinoma, although in recent years there has been renewed interest in surgery for small-cell carcinoma.
Nitrogen mustard was first used in 1942 and Karnofsky'8 later reported effective palliation with this agent in 31 cases ofbronchogenic carcinoma. The responses of anaplastic tumours were more dramatic than in the group of squamous carcinomas, but were short-lived and could not be made more durable by the addition of local radiotherapy. To this day the question of whether consolidation thoracic irradiation after induction chemotherapy produces a survival advantage remains open.
In 1969 Green'9 showed that intravenous cyclophosphamide was superior to placebo in patients with small cell carcinoma and in the years following this cyclophosphamide was used increasingly as initial treatment for small cell lung cancer. As new drugs became available and as clinical experience increased so combination regimens were introduced which proved to be superior in terms of response rate and survival to single agent therapy20. A review of the results of published trials with combination chemotherapy2l in 1977 showed an overall response rate of 60%, with a complete response rate of 23% and median survival of 31 weeks. Between 1978 and 1988 several questions were addressed in a large number of randomized clinical trials, including the value of chest radiotherapy after chemotherapy, prophylactic cranial irradiation, alternating chemotherapy regimens and increased intensity of induction chemotherapy. Preliminary indications were that there were no major advances in this period in respect of improvement in long-term survival22 but several new drugs were found to have activity in small cell lung cancer, notably cisplatinum, etoposide (VP-16), teniposide (VM-26), ifosfamide and carboplatin (JM-8)23.
Several recent studies have identified the pretreatment determinants of prognosis in large groups of small cell lung cancer patients treated on various protocols in several centres24-26. All have confirmed that extent of disease is one of the most important but other factors including performance status, age and biochemical variables are also significant. Use of these prognostic factors may be helpful in the selection ofpatients for clinical trials using advanced treatment modalities such as high dose chemotherapy with or without autologous bone marrow transplantation and alternating non-cross-resistant combination chemotherapy27. With contemporary chemotherapy it is possible to obtain long-term disease firee remission of over 3 years in 5-10% of patients, which represents a five-fold increase in survival in the last 10-15 years8.
Small cell tumour biology Some of the major advances in small cell carcinoma in recent years have been in the field of tumour biology. It has proved possible to establish small cell carcinoma cell lines in the laboratory which have revealed the presence of tumour markers including L-dopa decarboxylase, neuron specific enolase, creatine kinase BB isoenzyme and bombesin with selective loss of these occurring in so-called 'variant' sub-types. Variant cell lines have also been shown to be associated with amplification of the c-myc oncogene29 resulting in selective growth advantage and more vigorous growth than 'classic' cells lines not possessng such amplification. Bombesin has been found to be an autocrine growth factor for small cell carcinoma and antibodies raised against this peptide are being explored as potential anti-cancer therapy30. It remains to be shown whether other tumour markers, including cellular oncogenes are a feasible target for anti-cancer drugs.
A deletion ofthe short arm ofchromosome-3 appears specific for small cell lung cancer but it is unknown whether this results in neoplastic transformation due to uncovering of a recessive oncogene, loss of a suppressor gene or another mechanism. Small cell lung cancer cell lines exhibit reduced expression of some class I HLA antigens and it has been postulated that if this also occurs in vivo then it may reduce the efficiency of cell-mediated cytotoxicity towards tumour cells. Upregulation of these antigens by biological agents such as the interferons may improve host immune mediated recognition and elimination of SCLC cells30. An international workshop on Lung Cancer Antigens was formed in 1986 which defined clusters of antibodies recognizing the same SCLC antigens31. Definition of such antigens and production of monoclonal antibodies directed against them is a possible means for developing targetted tumour therapy and may also be useful in the context of high dose chemotherapy with autologous marrow transplant for bone marrow purging. These advances may lead to the development of improved criteria for diagnosis and prognosis and also novel approaches to treatment for small cell carcinoma in the future.
Conclusion
Small cell lung cancer exemplifies the progress that has been made in cancer management in recent years. Beginning with improved definition based on morphological and biological criteria and proceeding to the identification of active treatments there has been considerable effort to refine treatment so as to control both local and metastatic disease requiring developments in systemic therapy and the use of multiple treatment modalities. Much has been learnt about the nature of the small cell carcinoma and definition of growth factors, surface antigens and other biological properties has indicated directions along which future treatments might develop.
